A Century of Excellence
Discover the history of one of the nation's first cancer hospitals.
Read more »
Collection and distribution of human subject biosamples.
Read more »
Phase 1 Clinical Trials
Read more »
Molecular Medicine at Fox Chase
Read more »
The Corporate Alliances team within the Office of Research and Development Alliances. Left to right: Clarissa Ceruti, Kelly Smith, Jim Thompson, Kurt Schwinghammer, Marianne Weyhmuller, Julie Sharp, Inna Khartchenko
Industrial collaborations with researchers at Fox Chase provide a myriad of benefits for both partners. Technology licensing fulfills our obligation to make scientific discoveries available for the public good while generating income for our research, educational, and cancer treatment programs. A company gains the opportunity to interact with Fox Chase's world class scientists and clinicians while reducing its internal costs of research and development. Fox Chase offers several avenues for collaborating with industrial partners to develop our technologies. For further information, or to pursue a dialog about partnering with Fox Chase, please contact Kurt Schwinghammer, Inna Khartchenko or Clarissa Ceruti.
These are grants or contracts from a company that sponsors research at Fox Chase. These can be for specific projects in one laboratory (e.g. to investigate the role of a gene in cell growth), or for multi-disciplinary endeavors such as genomics and bioinformatics. Sponsored research represents a commitment by both parties to promote investigations in a particular area, and often result in proprietary positions.
Licenses granting a company the right to "make, use, and sell" products in a particular field based on the licensed technology. Equitable terms are negotiated between the company and Office of Corporate Alliances which ensure that a given technology is aggressively developed into a product that benefits the public. At the same time, the financial rewards reaped by the Center are used to promote further research and education. The company benefits by reducing its R&D costs, ameliorating the risk associated with R&D, and gaining the exclusivity needed to bring a product to market and make a profit. Current List
Commercial Evaluation/Option Agreements
In some instances, a technology may be so embryonic that a company may wish to evaluate the commercial feasibility for a period of time. We can provide that opportunity under an option agreement that allows the company to assess the commercial potential and decide whether they want to license the technology.
Clinical Trials at the Fox Chase Cancer Center
The Fox Chase Cancer Center and Fox Chase Cancer Center Partners offer many opportunities for clinical research related to cancer. At any given time, approximately 150 studies are open for patient enrollment with another 150 remaining active for patient monitoring. Research ranges from investigational new drugs (phase I trials) through focused phase II, and large, multicenter, randomized phase III trials.
Approximately one third of our studies are sponsored by pharmaceutical companies, one third are Fox Chase investigator initiated, and one third are sponsored by national cooperative groups such as the Eastern Cooperative Oncology Group (ECOG), Gynecologic Oncology Group (GOG), and Radiation Therapy Oncology Group (RTOG). Major primary sites include gastrointestinal, lung, breast, and gynecologic.
Material Transfer Agreements
Exchange of research materials (cell lines, clones, et cetera) promotes collaboration between scientists in both academia and industry. Material transfer agreements define and protect the rights of both parties with respect to the transferred materials.
MTA's for materials coming into or going out from Fox Chase are reviewed and negotiated by the Office of Corporate Alliances to ensure that they conform with Fox Chase intellectual property and research policies. Companies interested in either supplying or receiving materials from Fox Chase staff members should contact our office to coordinate the exchange.
Academic material transfers are also coordinated by our office. We are committed to expediting these agreements for our researchers with as little "red tape" as possible.
Printed Material and Software Licensing
Fox Chase has many educational materials pertaining to all aspects of cancer detection, care and treatment available for copyright licensing. In addition, we have developed software for use in clinical data management and other areas. Please contact our office for more information.
Various techniques and devices have been developed at the Fox Chase Cancer Center. The Fox Chase name can be a valuable asset in marketing products associated with these techniques.
Fox Chase technologies by themselves or grouped with other technologies can provide the critical mass needed to start new businesses. Start-ups foster economic development in the community, bring a technology to market more quickly, increase the value of a technology by financing further development, and aid basic research. Start-ups require an enormous investment of management time, as well as substantial scientific, financial, and administrative efforts. Thus, the investment of time and effort in developing a new business must be weighed against the potential for commercial success versus other avenues.
Fox Chase is poised to work with potential partners to form new businesses around a platform technology or group of technologies. Our past efforts in this realm have been successful, and we are enthusiastic about this mode of transferring technology to the marketplace.